Annovis Bio is a clinical-stage pharmaceutical company with a focus on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases, as well as other neurodegenerative diseases. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease, while BNC targets late stage AD and may stabilize the decline. The lead compound, ANVS-401, has shown promising clinical signals in reducing and normalizing the levels of neurotoxic proteins back to the levels seen in healthy volunteers and statistically lowering inflammation. The company is presently conducting a Phase 2a study in AD patients in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group and plans to initiate a second Phase 2a proof-of-concept study of ANVS-401 in the first quarter of 2020 with 50 PD patients.